BidaskClub Downgrades Alnylam Pharmaceuticals (ALNY) to Hold

Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday.

Several other equities analysts also recently weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $85.00 target price (down previously from $98.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 7th. BMO Capital Markets restated an “outperform” rating and issued a $99.00 price objective (down from $105.00) on shares of Alnylam Pharmaceuticals in a research report on Wednesday, September 6th. Instinet began coverage on shares of Alnylam Pharmaceuticals in a research report on Friday, September 15th. They issued a “reduce” rating and a $56.00 price objective for the company. Piper Jaffray Companies restated an “overweight” rating and issued a $110.00 price objective (down from $126.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, September 7th. Finally, Leerink Swann reiterated a “market perform” rating and set a $72.00 target price (down from $83.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, September 8th. They noted that the move was a valuation call. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and sixteen have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $121.85.

Alnylam Pharmaceuticals (ALNY) opened at $124.57 on Thursday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 9.83 and a current ratio of 9.83. Alnylam Pharmaceuticals has a 12 month low of $35.98 and a 12 month high of $147.63.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.11). The business had revenue of $17.10 million during the quarter, compared to analysts’ expectations of $28.15 million. Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. Alnylam Pharmaceuticals’s revenue for the quarter was up 24.8% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.21) EPS. research analysts forecast that Alnylam Pharmaceuticals will post -5.21 EPS for the current fiscal year.

In related news, SVP Laurie Keating sold 30,000 shares of the stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $135.89, for a total value of $4,076,700.00. Following the completion of the sale, the senior vice president now directly owns 41,500 shares of the company’s stock, valued at approximately $5,639,435. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Barry E. Greene sold 76,815 shares of the stock in a transaction that occurred on Wednesday, September 20th. The shares were sold at an average price of $100.00, for a total transaction of $7,681,500.00. Following the sale, the president now directly owns 165,399 shares of the company’s stock, valued at $16,539,900. The disclosure for this sale can be found here. Insiders have sold a total of 393,212 shares of company stock valued at $48,109,436 in the last ninety days. Insiders own 4.30% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. State of Wisconsin Investment Board grew its holdings in Alnylam Pharmaceuticals by 0.7% during the 2nd quarter. State of Wisconsin Investment Board now owns 15,012 shares of the biopharmaceutical company’s stock valued at $1,197,000 after buying an additional 100 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Alnylam Pharmaceuticals by 7.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 167 shares during the last quarter. Utah Retirement Systems boosted its position in shares of Alnylam Pharmaceuticals by 1.5% during the 2nd quarter. Utah Retirement Systems now owns 13,800 shares of the biopharmaceutical company’s stock valued at $1,100,000 after acquiring an additional 200 shares during the last quarter. Prudential Financial Inc. boosted its position in shares of Alnylam Pharmaceuticals by 4.8% during the 2nd quarter. Prudential Financial Inc. now owns 4,404 shares of the biopharmaceutical company’s stock valued at $351,000 after acquiring an additional 200 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its position in shares of Alnylam Pharmaceuticals by 0.8% during the 2nd quarter. Alliancebernstein L.P. now owns 47,873 shares of the biopharmaceutical company’s stock valued at $3,818,000 after acquiring an additional 398 shares during the last quarter. 88.43% of the stock is owned by institutional investors and hedge funds.

WARNING: “BidaskClub Downgrades Alnylam Pharmaceuticals (ALNY) to Hold” was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://www.chaffeybreeze.com/2017/12/07/bidaskclub-downgrades-alnylam-pharmaceuticals-alny-to-hold.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply